Supplementary Table 2. Correlation of prevalence of EpCAM/CD49 with breast cancer prognosis (multivariate analysis).
| No. (%) | DFS | OS | |||
|---|---|---|---|---|---|
| p-value | HR (95% CI) | p-value | HR (95% CI) | ||
| EpCAM-/CD49f+ (%) | 150 | 0.010 | 0.002 | ||
| - (0) | 103 (68.7) | 1 | 1 | ||
| + ( > 0) | 47 (31.3) | 2.070 (1.188-3.608) | 3.235 (1.551-6.748) | ||
| EpCAM+/CD49f+ (%) | 150 | 0.061 | 0.042 | ||
| - (0) | 110 (73.3) | 1 | 1 | ||
| + ( > 0) | 40 (26.7) | 1.813 (0.974-3.377) | 2.250 (1.031-4.907) | ||
| EpCAM+/CD49f- (%) | 150 | 0.267 | 0.455 | ||
| - (0) | 94 (22.3) | 1 | 1 | ||
| + ( > 0) | 56 (77.7) | 1.357 (0.792-2.323) | 1.308 (0.647-2.646) | ||
| EpCAM-/CD49f- (%) | 150 | 0.302 | 0.444 | ||
| - (0) | 26 (17.3) | 1 | 1 | ||
| + ( > 0) | 124 (82.7) | 0.713 (0.376-1.351) | 0.721 (0.312-1.666) | ||
EpCAM=epithelial cell adhesion molecule; DFS=disease-free survival; OS=overall survival; HR=hazard risk; CI=confidence interval.